Oncostellae

📍 Santiago de Compostela, Spain🗓 Founded 2013👥 12 employees💰 Last funded Jan 2023
Pharmaceutical Manufacturing🌐 oncostellae.com
Website LinkedIn
Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting big market indications in immunology and oncology. After successful proof-of-concept studies in early clinical phases, seeking license agreements with pharmaceutical companies for further clinical development and commercialization. ---- PIPELINE: ---- Two of Oncostellaes drug candidates have reached advanced development stages and are currently being evaluated in clinical studies in patients: OST-122 is a safe, non-systemic JAK inhibitor for the treatment of Ulcerative Colitis (Phase 2a), and OST-499 is a GR antagonist for the treatment of colon cancer and other solid tumors (Phase 1). Positive data on safety and efficacy that are expected to be available by the end of 2023 would provide outlicensing opportunities.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Spain
2
Frequently asked questions
Who invested in Oncostellae?
Oncostellae has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Oncostellae last raise funding?
The most recent investment in Oncostellae recorded on gritt.io was in January 2023.
When was Oncostellae founded?
Oncostellae was founded in 2013.
What industry is Oncostellae in?
Oncostellae operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Oncostellae based?
Oncostellae is headquartered in Santiago de Compostela, Spain.